Most barrier-focused studies in psoriasis have either concentrated on IL-23 pathway inhibition or a combination of different TNF-α antagonists, and detailed site-specific TEWL and pH dynamics during adalimumab monotherapy remain insufficiently characterized. Here, TNF is linked to psoriasis.